Takeda Pharmaceutical Company Limited Adjustments For Income Tax Expense
Takeda Pharmaceutical Company Limited (TKPHF) reported Adjustments For Income Tax Expense of JPY 66.94 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForIncomeTaxExpense · last filed 2025-06-25
| Period end | Adjustments For Income Tax Expense 12 month | Adjustments For Income Tax Expense 12 month as first filed |
|---|---|---|
| 2025-03-31 | 66.94B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | -91.41B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 58.05B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | 72.41B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | -9.94B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | -105.04B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | -7.47B JPY 20-F · filed 2021-06-29 | -14.12B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 30.50B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | 27.83B JPY 20-F · filed 2019-06-27 |